Novo Nordisk's (NVO) acquisition of three Catalent (CTLT) production sites to close soon as its parent wins regulatory nod ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy. According to the ...

Danish pharma giant Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, is set to boost production with a ...

Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent ...

Catalent (CTLT) stock rises on reports of imminent $16.5 billion sale to Novo Holdings with FTC approval and EU Commission ...

Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences ...